Effect of phosphodiesterase inhibitors on platelet function [PDF]
Biochemistry and Biophysics ReportsPhosphodiesterase enzymes (PDEs) play a pivotal role in regulating platelet activity by modulating intracellular levels of cAMP and cGMP. Modulation of PDE-2, -3 and -5 activity by suitable inhibitors has been found to reduce platelet activity, and thus ...
Ravi Hochuli +7 more
doaj +2 more sources
Effect of some inhibitors of platelet aggregation on platelet nucleotides [PDF]
Biochemical Journal, 1969 Ge. Ball +3 more
openalex +4 more sources
Elderly patients are hyperresponsive to potent P2Y12 inhibitors [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Aging has recently been associated with increased basal platelet activation and platelet hyperreactivity in response to adenosine diphosphate (ADP) but with decreased platelet response to thrombin receptor stimulation in individuals without ...
David Mutschlechner +7 more
doaj +2 more sources
Fucosylated Glycosaminoglycan Oligosaccharide HS14, Derived from Sea Cucumbers, Is a Novel Inhibitor of Platelet Toll-like Receptor 2 [PDF]
Marine Drugs(1) Background: Toll-like receptor 2 (TLR2) on platelets is increasingly recognized as a pivotal mediator in infection-induced platelet activation and aggregation, contributing to both inflammatory and thrombotic diseases.
Huifang Sun +8 more
doaj +2 more sources
Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease [PDF]
Endocrinology and Metabolism, 2022 Background The role of aspirin in primary cardiovascular disease prevention in patients with diabetes remains controversial. However, some studies have suggested beneficial effects of cilostazol on cardiovascular disease in patients with diabetes.
Sangmo Hong +2 more
doaj +1 more source
Aprobation of platelet aggregation inhibitor from Echis multisquamatis snake venom in vitro, in vivo and ex vivo [PDF]
Biotechnologia Acta, 2023 Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients.
Zhelavskyi M. A. +3 more
doaj +1 more source
Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation [PDF]
Blood, 1978 Abstract The possible participation of proteases in human platelet aggregation was explored using various protease inhibitors and substrates. Protease inhibitors used included naturally occurring inhibitors of serine proteases and synthetic inhibitors that modify the active site of protease.
K Naito, N Yoshida, N Aoki
openaire +4 more sources
Frontiers in Cardiovascular Medicine, 2022 PurposePrevious trials have demonstrated that ticagrelor was superior to clopidogrel in acute coronary syndrome (ACS) patients. However, several recent studies showed that ticagrelor was associated with a significantly higher risk of bleeding compared ...
Wenxing Peng +3 more
doaj +1 more source
The search of compounds with antiaggregation activity among S-esters of thiosulfonic acids [PDF]
The Ukrainian Biochemical Journal, 2015 According to the current understanding, the hyperactivation of platelets may lead to increased intravascular coagulation and thrombosis. Today a relevant issue is the search for new anti-thrombotic agents that are able to modulate the activity of ...
T. I. Halenova +8 more
doaj +1 more source
Nature Communications, 2020 Current inhibitors of platelet integrin αIIbβ3 cause excessive bleeding, which limited their clinical use in cardiac patients. Here the authors design pure orthosteric αIIbβ3 inhibitors that prevent platelet aggregation and thrombosis without causing ...
Brian D. Adair +9 more
doaj +1 more source